The Effects of Pioglitazone on Biochemical Markers of Bone Turnover in the Patients with Type 2 Diabetes

Table 3

Subgroup analyses of bone turnover after pioglitazone treatment in male patients with type 2 diabetes.

	<50 yrs (𝑛=14)		≥50 yrs (𝑛=19)
	Before therapy	After therapy	Before therapy	After therapy
Ca^2+ (mmol/L)	2.3±0.1	2.3±0.08	2.3±0.07	2.3±0.07
P^3− (mmol/L)	1.1±0.1	1.2±0.1	1.1±0.1	1.1±0.1
BAP (μgU/L)	13.2±5.7	13.0±6.2	14.1±5.9	13.5±5.5
P1NP (μg/L)	38.1±9.5	35.8±9.9	31.7±10.0	29.1±9.8
OC (ng/mL)	10.8±4.8	9.9±3.5	8.4±3.2	8.2±3.1
CTX (ng/mL)	0.37±0.11	0.35±0.14	0.29±0.14	0.27±0.14

Data are mean ± SD. BAP: bone-specific alkaline phosphatase; P1NP: procollagen type 1 N-terminal propeptide; OC: osteocalcin; CTX: C-terminal telopeptide of type 1 collagen.